NCT00089154View on ClinicalTrials.gov

Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

October 31, 2005

Conditions
Noncontiguous Stage II Small Lymphocytic LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Small Lymphocytic Lymphoma
Interventions
BIOLOGICAL

apolizumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (2)

43210

Ohio State University Medical Center, Columbus

92093-0820

Chronic Lymphocytic Leukemia Research Consortium (CRC), La Jolla

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00089154 - Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter